Skip to main content
Home > Week in Review > Clinical Status

Chronological Index of : Clinical Status

 Current Issue
  • subcutaneous ALX-0061: Phase Ib started

    Ablynx N.V. (Euronext:ABLX), Ghent, Belgium Product: subcutaneous ALX-0061 Business: Inflammation Molecular target: Interleukin-6 (IL-6) receptor (CD126) Description: Subcutaneous nanobody against IL-6 receptor (CD126) …

    Published on 5/5/2014
  • Tasquinimod: Phase III started

    Active Biotech AB (SSE:ACTI), Lund, Sweden Ipsen Group (Euronext:IPN; Pink:IPSEY), Boulogne-Billancourt, France Product: Tasquinimod (TASQ) (ABR-215050) Business: Cancer Molecular target: S100 calcium binding protein A9…

    Published on 5/5/2014
  • Tecarfarin: SPA received

    Armetheon Inc., Menlo Park, Calif. Product: Tecarfarin (formerly ATI-5923) Business: Cardiovascular Molecular target: Vitamin K epoxide reductase complex subunit 1 (VKORC1) Description: Long-acting inhibitor of vitamin …

    Published on 5/5/2014
  • Tretinoin gel: Completed Phase II enrollment

    Phosphagenics Ltd. (ASX:POH; OTCQX:PPGNY), Melbourne, Australia Product: Tretinoin gel, TPM/Retinoic Acid, TPM/Tretinoin Business: Dermatology Molecular target: Not applicable Description: Tretinoin formulated with …

    Published on 5/5/2014
  • TRV130: Phase II started

    Trevena Inc. (NASDAQ:TRVN), King of Prussia, Pa. Product: TRV130 Business: Neurology Molecular target: Mu opioid receptor (OPRM1) (MOR) Description: G protein-biased mu opioid receptor (OPRM1; MOR) ligand Indication: …

    Published on 5/5/2014
  • Ampion: Completed Phase III enrollment

    Ampio Pharmaceuticals Inc. (NYSE-M:AMPE), Greenwood Village, Colo. Product: Ampion Business: Autoimmune Molecular target: NMDA receptor; Serotonin (5-HT2C) receptor Description: A cyclic aspartate-alanine dipeptide …

    Published on 2/24/2014
  • Anthim: Completed pivotal trial enrollment

    Elusys Therapeutics Inc., Pine Brook, N.J. Product: Anthim (ETI-204) Business: Infectious Molecular target: Bacillus anthracis protective antigen Description: High-affinity humanized mAb against the Bacillus anthracis …

    Published on 2/24/2014
  • Anthim: Completed pivotal trial enrollment

    Elusys Therapeutics Inc., Pine Brook, N.J. Product: Anthim (ETI-204) Business: Infectious Molecular target: Bacillus anthracis protective antigen Description: High-affinity humanized mAb against the Bacillus anthracis …

    Published on 2/24/2014
  • Anthim: Completed pivotal trial enrollment

    Elusys Therapeutics Inc., Pine Brook, N.J. Product: Anthim (ETI-204) Business: Infectious Molecular target: Bacillus anthracis protective antigen Description: High-affinity humanized mAb against the Bacillus anthracis …

    Published on 2/24/2014
  • AZD6765: Development discontinued

    AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: AZD6765 Business: Neurology Molecular target: NMDA receptor Description: NMDA receptor antagonist Indication: Treat major depressive disorder (MDD) Endpoint: …

    Published on 2/24/2014
  • Brilacidin: Phase IIb started

    Cellceutix Corp. (OTCQB:CTIX), Beverly, Mass. Product: Brilacidin (formerly PMX-30063) Business: Infectious Molecular target: NA Description: Synthetic defensin mimetic bactericidal antibiotic Indication: Treat acute …

    Published on 2/24/2014
  • CicloMulsion: Completed Phase III enrollment

    NeuroVive Pharmaceutical AB (SSE:NVP), Lund, Sweden Sihuan Pharmaceutical Holdings Group Ltd. (HKSE:0460), Haikou, China Product: CicloMulsion Business: Cardiovascular Molecular target: NA Description: Cremophor-free IV…

    Published on 2/24/2014
  • EBI-005: Phase III started

    Eleven Biotherapeutics Inc. (NASDAQ:EBIO), Cambridge, Mass. Product: EBI-005 Business: Ophthalmic Molecular target: Interleukin-1 (IL-1) Description: Interleukin-1 (IL-1) receptor antagonist Indication: Treat dry eye …

    Published on 2/24/2014
  • Fzd8-Fc: Phase Ib started

    OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), Redwood City, Calif. Product: Fzd8-Fc (OMP-54F28) Business: Cancer Molecular target: NA Description: Wnt signaling antagonist Indication: First-line treatment of locally …

    Published on 2/24/2014
  • Fzd8-Fc: Phase Ib started

    OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), Redwood City, Calif. Product: Fzd8-Fc (OMP-54F28) Business: Cancer Molecular target: NA Description: Wnt signaling antagonist Indication: Treat recurrent platinum-sensitive …

    Published on 2/24/2014
  • GLPG0974: Completed Phase IIa enrollment

    Galapagos N.V. (Euronext:GLPG; Pink:GLPYY), Mechelen, Belgium Product: GLPG0974 Business: Autoimmune Molecular target: Free fatty acid receptor 2 (FFAR2) (GPR43) Description: Small molecule inhibitor of free fatty acid …

    Published on 2/24/2014
  • ItMSCs: Phase IIa started

    Stemedica Cell Technologies Inc., San Diego, Calif. Product: ItMSCs Business: Cardiovascular Molecular target: NA Description: Transplanted ischemic-tolerant mesenchymal stem cells Indication: Treat acute myocardial …

    Published on 2/24/2014
  • ItMSCs: Phase III started

    Stemedica Cell Technologies Inc., San Diego, Calif. Product: ItMSCs Business: Cardiovascular Molecular target: NA Description: Transplanted ischemic-tolerant mesenchymal stem cells Indication: Treat acute myocardial …

    Published on 2/24/2014
  • L-DOS47: Phase I/II ongoing

    Helix BioPharma Corp. (TSX:HBP), Aurora, Ontario Product: L-DOS47 Business: Cancer Molecular target: Not available Description: Plant-derived urease combined with a highly specialized antibody agent to identify lung …

    Published on 2/24/2014
  • Mepolizumab: Phase III started

    GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Product: Mepolizumab (Bosatria) (SB-240563) Business: Inflammation Molecular target: Interleukin-5 (IL-5) Description: Humanized IgG mAb against IL-5 Indication: …

    Published on 2/24/2014
  • Nerventra laquinimod: Phase III discontinued

    Active Biotech AB (SSE:ACTI), Lund, Sweden Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), Petah Tikva, Israel Product: Nerventra laquinimod (SAIK-MS) Business: Autoimmune Molecular target: S100 calcium binding protein…

    Published on 2/24/2014
  • OMS824: Phase II started

    Omeros Corp. (NASDAQ:OMER), Seattle, Wash. Product: OMS824, OMS643762 Business: Neurology Molecular target: Phosphodiesterase-10 (PDE-10) Description: Selective inhibitor of phosphodiesterase-10 (PDE-10) Indication: …

    Published on 2/24/2014
  • ONT-380: Phase Ib started

    Array BioPharma Inc. (NASDAQ:ARRY), Boulder, Colo. Oncothyreon Inc. (NASDAQ:ONTY), Seattle, Wash. Product: ONT-380, ARRY-380 Business: Cancer Molecular target: Epidermal growth factor receptor 2 (EGFR2) (HER2) (ErbB2) (…

    Published on 2/24/2014
  • PRO 140: Phase IIb start

    CytoDyn Inc. (OTCBB:CYDY), Vancouver, Wash. Product: PRO 140 Business: Infectious Molecular target: CC chemokine receptor 5 (CCR5) (CD195) Description: Humanized mAb against CC chemokine receptor 5 (CCR5) Indication: …

    Published on 2/24/2014
  • RGI-2001: Phase I/II ongoing

    Regimmune Corp., Tokyo, Japan Product: RGI-2001 (formerly ToleroVax) Business: Transplant Molecular target: Natural killer T cells Description: Liposomal formulation of KRN7000, a synthetic derivative of alpha-…

    Published on 2/24/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993